Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)

Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;
•2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;
•3) Inpatients aged 18 to 75 years male or female;
•4) Volunteer to receive treatment under their own scheme and sign informed consent.

•1) Patients with mild, severe or critical novel coronavirus disease;
•2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, severe malnutrition, liver and kidney disease, blood disease, nervous system Diseases and endocrine diseases; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;
•3) Those who are allergic to the research drug and its main ingredients;
•4) pregnant or lactating women;
•5) Those who have difficulty taking medicine orally.

发起方

Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine